Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T75888
|
||||
Former ID |
TTDS00433
|
||||
Target Name |
Carnitine O-palmitoyltransferase I
|
||||
Gene Name |
CPT1B
|
||||
Synonyms |
CPT; CPT I; CPT-1; CPTI-L; Carnitine o-palmitoyltransferase-1; Carnitine palmitoyl-transferase I; Carnitine palmitoyltransferase I; CPT1B
|
||||
Target Type |
Successful
|
||||
Disease | Angina pectoris [ICD9: 413; ICD10: I20] | ||||
Diabetes [ICD9: 253.5, 588.1; ICD10: E23.2, N25.1] | |||||
Heart failure [ICD9: 428; ICD10: I50] | |||||
Nutritional deficiency [ICD9: 260-269; ICD10: E40-E64] | |||||
Obesity [ICD9: 278; ICD10: E66] | |||||
Psoriasis [ICD9: 696; ICD10: L40] | |||||
Function |
Catalyzes the transfer of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidationin the mitochondrion. Plays an important role in triglyceride metabolism.
|
||||
BioChemical Class |
Acyltransferase
|
||||
Target Validation |
T75888
|
||||
UniProt ID | |||||
EC Number |
EC 2.3.1.21
|
||||
Sequence |
MAEAHQAVAFQFTVTPDGVDFRLSREALKHVYLSGINSWKKRLIRIKNGILRGVYPGSPT
SWLVVIMATVGSSFCNVDISLGLVSCIQRCLPQGCGPYQTPQTRALLSMAIFSTGVWVTG IFFFRQTLKLLLCYHGWMFEMHGKTSNLTRIWAMCIRLLSSRHPMLYSFQTSLPKLPVPR VSATIQRYLESVRPLLDDEEYYRMELLAKEFQDKTAPRLQKYLVLKSWWASNYVSDWWEE YIYLRGRSPLMVNSNYYVMDLVLIKNTDVQAARLGNIIHAMIMYRRKLDREEIKPVMALG IVPMCSYQMERMFNTTRIPGKDTDVLQHLSDSRHVAVYHKGRFFKLWLYEGARLLKPQDL EMQFQRILDDPSPPQPGEEKLAALTAGGRVEWAQARQAFFSSGKNKAALEAIERAAFFVA LDEESYSYDPEDEASLSLYGKALLHGNCYNRWFDKSFTLISFKNGQLGLNAEHAWADAPI IGHLWEFVLGTDSFHLGYTETGHCLGKPNPALAPPTRLQWDIPKQCQAVIESSYQVAKAL ADDVELYCFQFLPFGKGLIKKCRTSPDAFVQIALQLAHFRDRGKFCLTYEASMTRMFREG RTETVRSCTSESTAFVQAMMEGSHTKADLRDLFQKAAKKHQNMYRLAMTGAGIDRHLFCL YLVSKYLGVSSPFLAEVLSEPWRLSTSQIPQSQIRMFDPEQHPNHLGAGGGFGPVADDGY GVSYMIAGENTIFFHISSKFSSSETNAQRFGNHIRKALLDIADLFQVPKAYS |
||||
Structure |
2LE3
|
||||
Drugs and Mode of Action | |||||
Drug(s) | L-Carnitine | Drug Info | Approved | Nutritional deficiency | [468010], [536186] |
Perhexiline | Drug Info | Approved | Angina pectoris | [536403] | |
SDZ-CPI-975 | Drug Info | Discontinued in Phase 1 | Diabetes | [545960] | |
DB-200 | Drug Info | Terminated | Psoriasis | [548567] | |
Etomoxir | Drug Info | Terminated | Heart failure | [533432] | |
Pathways | |||||
KEGG Pathway | Fatty acid degradation | ||||
Fatty acid metabolism | |||||
PPAR signaling pathway | |||||
AMPK signaling pathway | |||||
Adipocytokine signaling pathway | |||||
Glucagon signaling pathway | |||||
PathWhiz Pathway | Fatty acid Metabolism | ||||
Reactome | RORA activates gene expression | ||||
PPARA activates gene expression | |||||
Import of palmitoyl-CoA into the mitochondrial matrix | |||||
WikiPathways | SIDS Susceptibility Pathways | ||||
Mitochondrial LC-Fatty Acid Beta-Oxidation | |||||
Nuclear Receptors Meta-Pathway | |||||
PPAR Alpha Pathway | |||||
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
Circadian Clock | |||||
Fatty Acid Beta Oxidation | |||||
AMPK Signaling | |||||
References | |||||
Ref 468010 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4780). | ||||
Ref 533432 | Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res. 1988 Dec;63(6):1036-43. | ||||
Ref 536186 | Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. | ||||
Ref 533432 | Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res. 1988 Dec;63(6):1036-43. | ||||
Ref 533757 | Comparison of the effects of carnitine palmitoyltransferase-1 and -2 inhibitors on rat heart hypertrophy. Cardioscience. 1994 Sep;5(3):193-7. | ||||
Ref 534566 | Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys. Am J Physiol. 1998 Feb;274(2 Pt 2):R524-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.